Welcome to our dedicated page for LB PHARMACEUTICALS SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LB PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LB PHARMACEUTICALS's regulatory disclosures and financial reporting.
Vida Ventures reporting persons recorded multiple transactions in LB Pharmaceuticals, Inc. (LBRX) on 09/12/2025. Series C preferred shares held by Vida entities converted into common stock immediately prior to the issuer's IPO under a conversion mechanism tied to the IPO price. Vida Ventures III, L.P. reported 547,648 common shares beneficially owned following conversion; Vida Ventures III-A, L.P. reported 1,262 common shares; Vida Ventures Management Co. LLC reported 1,434 common shares.
Additionally, purchases at $15.00 per share were reported: Vida Ventures III, L.P. acquired 332,566 common shares and Vida Ventures III-A, L.P. acquired 767 common shares, bringing Vida Ventures III total to 880,214 and Vida Ventures III-A to 2,029 beneficially owned shares as shown on the form.
LB Pharmaceuticals (LBRX) reports Phase 2 results for LB-102 showing statistically significant improvement on the PANSS overall score at 50 mg, 75 mg and 100 mg versus placebo and a favorable tolerability profile with mostly transient, mild-to-moderate adverse events. The company observed a statistically significant impact on negative symptoms at the 50 mg dose and exploratory post-hoc analyses supported cognitive benefits on CogState testing. Based on end-of-Phase 2 feedback, management believes the Phase 2 trial may serve as one of two pivotal trials and plans a single six-week, three-arm, inpatient, double-blind Phase 3 trial (50 mg, 100 mg, placebo) to start in Q1 2026 with ~400 U.S. patients across ~25 sites, primary endpoint change in PANSS at Day 42, topline data expected H2 2027 and an FDA meeting planned Q1 2028 if results are positive.
The company is also initiating LB-102 development in bipolar depression with a Phase 2 trial planned in Q1 2026 and topline data expected Q1 2028. Financially, recent periods show operating losses (e.g., pro forma net loss figures presented) and the company discloses pro forma as adjusted cash and marketable securities balances consistent with its offering plan to advance LB-102 into Phase 3 and other NDA-enabling studies.